The capacity of traditional noninvasive diagnostic procedures such as microhematuria testing and urine cytology to be used as stand-alone screening techniques for urothelial carcinoma is limited. New qualitative and quantitative molecular screening modalities can detect alterations that are often exclusively associated with this disease. Mitra and Cote propose incoporating both traditional approaches and molecular tests into a risk-based screening strategy.
- Anirban P. Mitra
- Richard J. Cote
